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INTRODUCTION 
It is apparent through the efforts of a number of investigators that ascorbic acid 
is involved in the metabolism and detoxification of numerous xenobiotics. Interestingly, 
the vitamin participates a t  a variety of levels, including the important hepatic electron 
transport systems, i.e., cytochrome P-450 mixed function oxygenase (MFO)’-’’ and 
flavin-containing monooxygenase ( FMO)’2-24; protection against covalent binding of 
“reactive intermediates” to macromolecular  protein^''^^; and more recently involve- 
ment in the metabolism and toxicological consequences of a most commonly used 
and abused drug, alcohol.s’d1.6’.66 Although the precise biochemical mechanism of the 
vitamin’s participation at  these levels warrants further investigation, the role of as- 
corbic acid in xenobiotic metabolism may have important consequences. 
RESULTS 
Ascorbic Acid and Hepatic Electron Transporf Systems 
It has been previously established and well documented that the hepatic microsomal 
cytochrome P-450 mixed function oxygenase (MFO) electron transport system is 
markedly reduced in vitamin C d e f i c i e n ~ y . ” ’ ~ ’ ~ ~ ~ ~  In addition, more recently, it has 
been demonstrated that the flavin-monooxygenase transport system ( FMO),22-24 re- 
sponsible for the metabolism of many nitrogen- and sulfur-containing xenobiotics, is 
also jeopardized in vitamin C deficiency (TABLE 1). Guinea pigs maintained on an 
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366 ANNALS NEW YORK ACADEMY OF SCIENCES 
ascorbic-acid-free diet had a significant reduction (45%) in the N-oxidation of di- 
methylaniline, a substrate for the FMO. Cytochrome P-450 was also reduced, whereas 
the microsomal heme-containing cytochrome b, and the flavin-containing b ,  reductase 
were not affected. The decrease in FMO could be differentiated from the decrease in 
the MFO system by the use of specific inhibitors, phenobarbital pretreatment, thermal 
treatment, and pH activity profiles. The effect of inhibitors is shown in FIGURES 1A 
and IB. The N-oxidation of dimethylaniline (DMA), a FMO substrate, was in fact 
stimulated (twofold) by 3 mM n-octylamine (FIG. lA),  while aniline, an MFO 
substrate, was inhibited 90%. Also, SKF-525A, another MFO inhibitor, caused a 
decrease of 60% in the metabolism of p-NO, anisole, an MFO substrate, and did not 
affect the N-oxidation of DMA (FIG. 1B). Phenobarbital pretreatment of guinea pigs 
did not induce FMO, while the MFO was induced twofold in both ascorbic-acid- 
supplemented and ascorbic-acid-deficient guinea pigs. The FMO could be selectively 
inactivated at 50°C (95%) ,  while the MFO was not significantly altered. In addition, 
FMO activity was reduced by 50% at pH 7.0 in preparations from both ascorbate- 
supplemented and ascorbic-acid deficient animals while no significant decrease of MFO 
activity was observed at this pH. In addition to the decrease in FMO due to  the 
deficiency of the vitamin, there was a further decrease in FMO activity in the deficient 
guinea pigs who had lost up to 10-15% of their body weight compared to ascorbic- 
acid-supplemented animals ( TABLE 2). Guinea pigs on an ascorbic-acid deficient diet 
that had no significant weight loss had a 40% reduction in FMO activity, while the 
ascorbic acid deficient animals that had lost 10-15% of their body weight had a 
reduction of 83%. 
Purification of the FMO from ascorbic-acid-deficient and ascorbic-acid-supple- 
mented guinea pig livers with DEAE cellulose and Blue-2-Agarose column chroma- 
tography resulted in two FMO fractions ( A  and B) in both cases. Fraction A was 
eluted with 0.35 M KCl, pH 7.8, and required exogenous FAD (0.05 mM) for optimal 
activity. The recovery of enzyme activity in the fraction from ascorbic-acid-deficient 
microsomal preparations was four times greater than microsomal preparations from 
ascorbic-acid supplemented guinea pigs. There was, however, a marked reduction in 
the quantity of FMO activity in the B fraction isolated from the ascorbic-acid-deficient 
microsomes: a 5% recovery compared to a 25% recovery for the ascorbic-acid- 
supplemented animals. Furthermore, subjection of purified preparations ( 30- to 120- 
fold; DEAE, Blue-2-Agarose, and 2', 5'-ADP Sepharose) to polyacrylamide gel elec- 
trophoresis resulted in a marked decrease in the quantity of protein banding at 56,000 
daltons in enzyme prepared from vitamin-C-deficient animals?4 
Purified FMO isolated from ascorbic-acid-deficient animals was unstable to freezing 
at - 20", whereas comparable preparations from ascorbic-acid-supplemented animals 
maintained over 90% of their activity up to 4 weeks. Furthermore, marked substrate 
inhibition occurred with enzyme prepared from the ascorbic-acid-deficient animals. 
At 2 mM DMA, the initial rate of the reaction as measured for 100 seconds was 
linear with time and comparable to  enzyme purified from the ascorbic-acid-supple- 
mented animals. However, this initial rate decreased at 400 seconds, a more than 
95% decrease with enzyme prepared from ascorbic-acid-deficient animals compared 
to a decrease of 40% with enzyme prepared from ascorbic-acid-supplemented ani- 
m a l ~ . ~ '  
Kinetic experiments with purified preparations from ascorbic-acid-deficient or sup- 
plemented animals indicated no significant difference in the affinity of either DMA 
or NADPH. The K ,  for DMA is 3.1 X M for enzyme prepared from ascorbic- 
acid-deficient animals and 3.2 x lo-' M for enzyme prepared from ascorbic-acid- 
supplemented animals. The K,,, for NADPH is 7.7 X M for ascorbic-acid- 
deficient and 3.8 X lo-' M for ascorbic-acid-supplemented animals for FMO activity 
associated with the B fraction. The apparent affinity for F A D  with purified FMO 
fraction A isolated from ascorbic-acid-deficient animals was 8.0 X 10- ' M.I4 
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FIGURE 1. (A.B) Effect of cytochrome P-450 inhibitors. Activity is measured as nmoles product 
per min per mg 12,000 x g  hepatic supernatant fraction. For DMA the N-oxide product was 
determined. p-Nu, p-nitroanisole. The average hepatic level of ascorbic acid in supplemented 
animals was 29 2 13 mg/100 g wet liver and 1.8 * 1.3 in the deficient animals. The data 
presented in the figure represent a typical experiment: H = plus ascorbate diet; 0 = no 
ascorbate diet; = SKF-525A, 1 mM; and 0 = n-octylamine, 3 mM. (From Brodfuehrer 
and Zannoni." Reprinted by permission of Biochemical Pharmacology.) 
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TABLE 2. Effect of Ascorbic Acid on Hepatic Flavin Monooxygenase" 
1 1 3 "  
FMO Livet Ascorbde 
Diet (nmol/ min /mg Protein) (mg/g Wet Liver wt) 
10-15% Weight Loss 
Deficient diet plus ascorbate 2.3 5 0.5 (6) 20.9 * 4.5 (6) 
Deficient diet, no ascorbate 1.9 It 1.4 ( 5 )  0.4 * 0.08' ( 5 )  
No Weight Loss 
Deficient diet plus ascorbate 22.0 2 6.6(7) 
Deficient diet, no ascorbate 0.8 0.3"'(7) 1.3 It 0.5(7) 
1.3 2 0.4d (7) 
' Dimethylaniline N-oxidation was assayed in the 12,000 g hepatic supernatant fraction. The 
'The mean value is significantly different (p < 0.001) compared to the corresponding plus 
'The mean value is significantly different (p < 0.02) compared to the corresponding plus 
The mean value is significantly different (p < 0.01) compared to the corresponding group 
"The mean value is significantly different (p < 0.02) compared to the corresponding group 
(Modified from Brodfuehrer and Zannoni.") 
numbers in parentheses are the number of animals and the data are means * SD. 
ascorbate group. 
ascorbate group. 
that lost weight. 
that lost weight. 
Ascorbic Acid and Covalent Binding 
Several laboratories have demonstrated a protective effect of ascorbic acid against 
covalent binding of reactive xenobiotic intermediates to macromolecular protein?s36 
Benzene and its metabolites exemplify this protective property of the vitamin. Upon 
chronic exposure, benzene produces hemopoietic toxicity resulting in reported cases 
of aplastic It has also been implicated as a human le~kemogen.'~ The 
toxicological consequences are thought to be via metabolic activation of benzene 
presumably through covalent binding of its metabolites to  protein.-' A possible 
metabolic pathway of benzene or its metabolite, phenol, leading to intermediates 
capable of covalent binding to protein is given in FIGURE 2. Benzene is oxidized to 
phenol, via the P-450 system, and phenol is further metabolized to catechol or hy- 
droquinone. Subsequent oxidation of phenol through le- steps lead to semiquinone 
intermediates and quinoid products. Peroxidases can catalize the oxidative steps; 
diaphorases are capable of reducing the quinoid products to hydroquinone and ca- 
techol. 
The ability of ascorbic acid to inhibit covalent binding of benzene or phenol 
metabolites is shown in TABLE 3. The inhibition by ascorbic acid was 75% with 
benzene. Glutathione caused marked inhibition of binding (95%). When phenol was 
incubated with hepatic microsomes, ascorbic acid or glutathione inhibited over 95%. 
Ascorbic acid can reduce quinoids while GSH can form adducts with them. The effect 
of ascorbic acid on covalent binding when phenol was incubated with horseradish 
peroxidase or myeloperoxidase isolated from guinea pig marrow is shown in TABLE 
4. HRP increased the covalent binding of phenol metabolites 30-fold and myeloper- 
oxidase increased it sixfold compared to the binding that occurred in their absence 
(TABLES 3 and 4). The binding was decreased over 95% by 1 mM ascorbic acid 
(TABLE 4). 
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The effect of DT diaphorase, ascorbic acid, or glutathione on the covalent binding 
of benzene or phenol metabolites is shown in FIGURES 3A and 3B. With benzene as 
the substrate, DT-diaphorase inhibited binding by only 18%, ascorbic acid inhibited 
it by 55% and GSH by 95% (FIG. 3A). In contrast, with phenol as the substrate, 
DT-diaphorase inhibited binding by 70% and ascorbic acid or GSH inhibited binding 
over 95% (FIG. 3B). Ascorbic acid or GSH had no significant effect on MFO me- 
tabolism of phenol or hydroquinone. However, ascorbic acid decreased the formation 
of phenol from benzene by 35%.35 
The effect of dietary ascorbic acid on the covalent binding of phenol metabolites 
with bone marrow, the target tissue for the toxicological events, was also determined. 
Covalent binding in bone marrow homogenates isolated from guinea pigs on an 
ascorbic-acid-free diet was fourfold higher than the bone marrow isolated from animals 
receiving 0.5 mg ascorbic acid per ml of drinking water (TABLE 5 ) .  In addition, the 
bone marrow ascorbic acid concentration was tenfold higher in the ascorbic-acid- 
treated animals while the GSH concentration in the bone marrow was not significantly 
different between the two groups. In view of these results, the effect of ascorbic acid 
P - 4 5 0  
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FIGURE 2. Proposed metabolic pathway of benzene or phenol leading to intermediates capable 
of covalent binding. (From Smart and Zannoni.Y Reprinted by permission of Molecular Phar- 
macologv. ) 
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TABLE 3. Effect of Ascorbic Acid and Glutathione on Covalent Binding of 
[ I4C]Benzene Metabolites to Hepatic Microsomal Protein in yitro 
Covalent Binding“ 
(pmol Phenol or 
Benzene Equivalents 
Additions Bound/min/mg Microsomal Protein) 
With [ ‘TIBenzene 
None (control with NADPH) 
Ascorbate (1 mM) 
Glutathione ( 1  mM) 
104.4 * 18.8 (3)b 
29.9 ? 3.4(3) 
3.3 t 2.2(3) 
With [I4C]Phenol 
None (control with NADPH) 
Ascorbate (1 mM) 
Glutathione (1 mM) 
252.7 k 12.3 (4) 
13.4 t 1.7(4) 
1.0 k 1.9 (4) 
[“CIPhenol (1 mM) or [‘‘CC]benzene (1  mM) were incubated with 0.7- 1.0 mg of washed hepatic 
microsomal protein isolated from phenobarbital-pretreated guinea pigs, NADPH (1 mM), and 
sodium phosphate buffer (100 mM, pH 7.4). The incubation was carried out for 10 or I5 min 
at 37’C. The total volume W ~ S  I mi. (Modified from Smart and Zannoni.”) 
a Values are expressed as x ? SD. 
The number in parentheses equals the number of experiments done in duplicate. 
on covalent binding of benzene metabolites after i.p. administration of [ I4C]benzene 
to guinea pigs placed on different dietary intakes of the vitamin was determined. In 
both liver and bone marrow, the binding decreased with higher tissue concentrations 
of ascorbic acid. In the liver the decrease was 50% with animals with 2.63 pmol 
ascorbate per g liver compared to animals with 0.28 pmol ascorbic acid per g (FIG. 
4). In the marrow the decrease was on the order of 30% with animals with 1.84 
pmol ascorbic acid per g marrow compared to animals with 0.12 pmol ascorbic acid 
per g marrow (FIG. 5 ) .  
Ascorbic Acid and Alcohol 
The involvement of ascorbic acid in alcohol metabolism and toxicity is of current 
interest and has been studied in several l abora tor ie~?’~”~ The principal enzymatic 
pathways for the oxidation of methanol or ethanol to their aldehydes include cytosolic 
alcohol dehydrogenase, which utilizes NAD+; cytosolic alcohol dehydrogenase, which 
utilizes H,O,; and the cytochrome P-450 mixed function oxygenase system (MFO), 
which requires NADPH and 0,. In vitro studies in our laboratory indicate that ascorbic 
acid can promote alcohol oxidation via a catalase-mediated reaction.” A comparison 
of this ascorbate-dependent alcohol oxidizing system to the alcohol dehydrogenase 
and the cytochrome P-450 microsomal system is shown in TABLE 6. The ascorbate- 
dependent system was over 200 times more active than the microsomal system for 
both methanol and ethanol; it was over 500 times more active for methanol and over 
100 times more active for ethanol compared to alcohol dehydrogenase. The effect of 
catalase inhibitors on the ascorbate-dependent alcohol oxidation is given in TABLE 7. 
Sodium azide and 3-amino-1,2,4-triazole were effective inhibitors with hepatic super- 
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natant, 12,000 X g hepatic pellet fractions, and when purified catalase was used as 
the enzyme source. When a peroxide generating system was used in place of ascorbic 
acid, the amount of inhibition with azide or triazole was comparable to the ascorbate- 
dependent system. A comparison of oxygen consumption, H,O, production, and 
alcohol oxidation utilizing ascorbic acid or a H,O, generating system is further 
evidence for an ascorbic-acid-catalase mediated reaction (TABLE 8). Hydrogen per- 
oxide was produced and 0, consumed with either ascorbic acid or a H,O, generating 
system. However, more oxygen was consumed with the ascorbic acid system than 
could be accounted for by its incorporation into H,O,. The active oxidizing species 
of catalase and H,O, is catalase-H,0, complex I, which can be measured spectro- 
photometrically." A comparison of alcohol oxidation and complex I formation utilizing 
either an H,O, generating system or ascorbic acid resulted in the formation of complex 
I. Furthermore, upon addition of alcohol the quantity of complex I was reduced in 
both cases." 
In view of the in vifm participation of ascorbic acid in alcohol metabolism, a 
determination of any in vivo protective effect of the vitamin against the toxicity of 
ethanol was of interest. The vitamin has been previously assessed, but to a limited 
degree, and in the main, in species that can synthesize it.5'.55.56 Yunice and coworkers 
did, however, find protection against hepatic steatosis by ascorbic acid in guinea pigs, 
a species which cannot synthesize the vitamin. In this study the animals were chron- 
ically infused with ethanoL6' The data presented in TABLE 9 are the result of an acute 
study in our laboratory in which serum enzymes, triglycerides, and liver weight to 
body weight ratios were determined after a single dose of ethanol given to guinea pigs 
on various regimens of ascorbic acid. Animals with hepatic ascorbic acid concentrations 
TABLE 4. Effect of HRP and Myeloperoxidase on Covalent Binding of ['4C]Phenol 







HRPb (0.12 unit), H,O, (8.8 mM) 
HRP (0.12 unit), H,O, (8.8 mM), 
Myeloperoxidaseb (0.17 unit), 
Myeloperoxidase (0.17 unit), 
ascorbate (1 mM) 
H,O, (8.8 mM) 
H,O, (8.8 mM), 
ascorbate (1 mM) 
H,O, (4.4 mM) 
8287.8 t 995.5 
50.8 * 23.3' 
1458.6 2 57.2 
70.6 t 20.1' 
114.1 2 32.1' 
["C]Phenol(I mM) was incubated with 0.7 mg of washed hepatic microsomal protein isolated 
from PB-pretreated guinea pigs and sodium phosphate buffer (100 mM, pH 7.4). The incubation 
was carried out for 5 min at 37°C. The total volume was 1 ml. (Modified from Smart and 
hnon i . " )  
"Values are means * standard deviation, n = 4, 1 unit = 1 p o l  of guaiacol oxidized/ 
min/mg; HRF' = 126 units/mg; guinea pig myeloperoxidase = 1.3 units/mg. 
*Control. 
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from 1 to 16 mg per 100 g liver had a 12-fold increase in SGOT levels. In contrast, 
animals with hepatic concentrations of the vitamin from 17 to 36 mg per 100 g liver 
had only a fivefold increase. The significance between the SGOT levels of these groups 
was p < 0.01. No correlation was found between the concentrations of the vitamin 
and levels of SGPT or serum triglycerides. In addition, there was no significant increase 
in ethanol clearance in animals with 1 to 16 mg ascorbic acid per 100 g liver (773 
5 104 pmol per 100 ml per h )  compared to animals with liver ascorbic acid con- 
centrations above 16 mg per 100 g liver (755 2 55 pmol per 100 ml per h). 
The data in TABLE 10 are the result of a study to determine the effect of ascorbic 
acid on chronic alcohol consumption in the guinea pig. Levels of SGOT and SGPT 
were significantly elevated in animals on the low ascorbic acid diet that had received 
alcohol: 120% and 250%. FIGURES 6A and 6B give a representative example of guinea 
pigs on a low or high ascorbic acid diet that received alcohol for 14 weeks. The 
development of hepatic steatosis is shown in the figure. Half of the animals on the 
low ascorbic acid diet also developed necrosis of their hepatocytes. None of the animals 
on the high ascorbic acid diet that received alcohol manifested these changes. 
Based on the in vivo animal studies demonstrating that ascorbic acid gave some 
protection against alcohol toxicity, and the in vitro studies demonstrating ascorbic 
acid involvement in alcohol oxidation, a determination was made on the effect of the 
vitamin on the consequences of acute alcohol consumption in man.’9 The study in- 
cluded ethanol clearance, toxicity, and behavioral patterns. Ascorbic acid pretreatment 
resulted in a significant increase in blood ethanol clearance. Ten subjects had a greater 
than 10% difference in clearance after vitamin pretreatment. Nine of these ten subjects 
had an 11 -74% increase in clearance; one had a 15% decrease. Of the remaining ten 
subjects, four had an increase in clearance of 1-lo%, five had a decrease of 1-lo%, 
and one had no change. In general, those individuals who had the largest increase in 
clearance with ascorbic acid pretreatment were those with the slowest clearance with 
the placebo (FIG. 7). In addition, ascorbic acid pretreatment resulted in a significantly 
higher level of serum triglycerides (FIG. 8). Eleven subjects had a greater than 20% 
difference in serum triglyceride levels after ascorbic acid pretreatment. Ten of these 
eleven subjects had a 36- 133% increase in triglyceride levels; one subject had a 30% 
decrease. Of the remaining nine subjects, four had a 10-20% increase, four had a 
1-20% decrease, and one had no change. Ascorbic acid pretreatment did not signif- 
icantly influence blood lactate : pyruvate ratios. 
FIGURE 3. (A) Effect of DT-diaphorase, ascorbate, or GSH on covalent binding of benzene 
metabolites with microsomes isolated from benzene-pretreated guinea pigs. The incubation con- 
tained [ “Clbenzene ( 1 mM), 2 units DT-diaphorase, ascorbate ( 1  mM), or GSH ( 1 mM). One 
unit of DT-diaphorase is defined as 1 pmol of p-benzoquinone reduced/min. Each value rep- 
resents the mean of three experiments done in duplicate * SD. (B) Effect of DT-diaphorase, 
ascorbate, or GSH on covalent binding of phenol metabolites with microsomes isolated from 
phenobarbital-pretreated guinea pigs. The incubation contained [ “Clphenol ( 1 mM), 2 units 
DT-diaphorase, ascorbate ( 1  mM), or GSH ( 1  mM). One unit of DT-diaphorase is defined as 
1 pmol p-benzoquinone reduced/min. Each value represents the mean of three experiments 
done in duplicate ? SD. (From Smart and Zannoni.” Reprinted by permission of Toxicology 
and Applied Pharmacology. ) 
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TABLE 5. Effect of Dietary Ascorbate on Covalent Binding of [“CIPhenol with Isolated 
Bone Marrow Preparations from Pair-Fed Guinea Pins”b 
Diet 
pmol Phenol mg% 
Equivalents Covalently Ascorbate 
Bound/S min‘ (Hepatic)‘ 
0.5 mg ascorbate per ml drinking water; 
ascorbate-free guinea pig chow 
882.3 * 105.5 34.1 * 17.9 
0.0 mg ascorbate per ml drinking water; 3108.7 * 159.2 3.1 k 1.6 
ascorbate-free guinea pig chow 
n = 5 individual guinea pigs per group. 
bAll incubations contained [“CJphenol (1 mM), sodium phosphate buffer (1 mM, pH 7.4). 
‘ Values are expressed as the means of five individual values 2 SD. 
(From Smart and Zannoni.”) 
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FlCURt 4. Corntent binding of the metabolites of benzene in the liver after i.p. administratkm 
ol[ “Clbenzene. [ “Clbenzene (660 mg/kg) was administered 12 and 6 hours before termination 
(0 three groups of guinea pigs on different dietary intakes of ascorbate. Ascorbate and binding 
values were determined for each guinea pig and the values are expressed as the mean 2 standard 
deviation;p < 0.01 with respect to 0.28 to 2.63 pmol/g ascorbate. (From Smart and Zannoni.M 
Reprinted by permission of Biochemical Pharmacologv. ) 
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FIGURE 5. Covalent binding of the metabolites of benzene in the bone marrow after i.p. 
administration of [ “Clbenzene. [ “CIBenzene (660 mg/kg) was administered 12 and 6 hours 
before termination to 3 groups of guinea pigs on different dietary intakes of ascorbate. Ascorbate 
and binding values were determined for each guinea pig and the values are expressed as the 
mean 2 standard deviation; p < 0.01 with respect to 0.12 to 1.84 p n o l / g  ascorbate. (From 
Smart and Zannoni.’6 Reprinted by permission of Biochemical Pharmacology. ) 
TABLE 6. Activities of Alcohol Dehydrogenase, Microsomal Ethanol-oxidizing System 
and the Ascorbate-Dependent Alcohol-oxidizing System with Methanol and Ethanol“ 
Specific Activityb 
(nmol CH,O or CH,CHO/min/mg Protein) 
Alcohol Microsomal Ethanol- Ascorbate-Dependent 
Substrate Deh ydrogenase oxidizing System Alcohol-oxidizing System 
Methanol 3 2 0.6 6 2 1  
Ethanol 11  2 1.0 6 2 1  
1720 2 200 
1570 2 140 
“ Assay conditions were as follows. Alcohol dehydrogenase: glycine buffer, 0.1 M, pH 9.5; 
NAD’, 1 mg/ml; guinea pig hepatic loJ g supernatant fraction, 1.0 mg protein; substrate, 12 
mM; total volume, 1.0 ml, 37°C. Microsomal ethanol-oxidizing system: sodium phosphate buffer, 
0.1 M, pH 7.5; NADPH, 2 mM; guinea pig hepatic microsomes, 1.0 mg protein; substrate, 200 
mM; total volume 1.0 ml, 37°C. Ascorbate-dependent alcohol-oxidizing system: Tris-HCI buffer, 
0.1 M + 10 mM 1,lO-phenanthroline, pH 8.5; ascorbate, 4 mM; guinea pig hepatic loJ g 
supernatant fraction, 15 pg protein; substrate, BOO mM; total volume, 1.0 ml, 37°C. 
Values are means of at least three experiments. 
(From Susick and Zannoni.”) 
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TABLE 7. Inhibition of the Ascorbate-Dependent Alcohol Oxidation” 
Specific Activity Inhibition 
Assay Condition Inhibitor (nmoles CH,O/min/mg) (%) 
Ascorbate 
lo5 g Supernatant no inhibitor 1,484 
sodium azide (2 mM) nd 100 
3-amino-1,2,4-triazole (100 mM) 541 63 
sodium azide nd 100 
3-amino-] ,2,4-triazole 258 66 
sodium azide nd 100 
3-amino- 1,2,4-triazole 12,804 12 
12,000 g Pellet no inhibitor 760 
Purified catalase no inhibitor 45,203 
H,O, Generating System 
10’ g Supernatant no inhibitor 861 
sodium azide 89 90 
3-amino- 1,2,4-triazole 328 62 
sodium azide 68 89 
3-amino-l,2,4-triazole 144 71 
sodium azide 1,944 94 
3-amino- 1,2,4-triazole 5,468 82 
12,000 g Pellet no inhibitor 634 
Purified catalase no inhibitor 30,009 
a Assay conditions: Tris-HCI buffer, 0.1 M + 1,lO-phenanthroline, 10 mM, pH 8.5; ascorbate, 
4 mM or H,O, generating system, 5.4 mg glucose + 0.1 mg glucose oxidase; guinea pig hepatic 
fraction, 15 pg protein, or purified beef liver catalase, 0.4 pg protein; methanol, 800 mM, total 
volume 1.0 ml, 37°C. 
Not detected. 
(From Susick and Zannoni.”) 
TABLE 8. Comparison of Methanol Oxidation, H,O, Production, and 0, Consumption 
with an H,O, Generating System and the Ascorbate Oxidation System” 
Methanol HZO, 0 2  
Oxidation Production Consumption 
Assay Conditions (nmol/ min/mg) (nmol/ min) (nmol/ min) 
H,O, generating system 223 * 14(3) 3.9 * 0.9(3) 4.3 0.6(5) 
Ascorbate 241 * 22(3) 6.9 2 0.4(4) 23.9 2 1.0(6) 
“Assay conditions were as follows. Methanol oxidation: Tris-HCI buffer, 0.1 M + 1,lO- 
phenanthroline, 10 mM, pH 8.5; ascorbate, 1 mM, or H,O, generating system, 30 mM glucose + 0.02 mg glucose oxidase; guinea pig hepatic 10’ g supernatant fraction, 15 pg protein; methanol, 
600 mM; total volume, 1.0 ml, 2YC. H,O, production: Tris-HCI buffer, 0.1 M + 1,lO-phen- 
anthroline, 10 mM, pH 8.5; ascorbate, 1 mM, or H,O, generating system, 30 mM glucose + 
0.04 mg glucose oxidase; boiled guinea pig hepatic lo5 g supernatant fraction, 30 pg protein; 
total volume 2.0 ml, 25°C. 0, consumption: Tris-HCI buffer, 0.1 M + ],lo-phenanthroline, 10 
mM, pH 8.5; ascorbate, 1 mM, or H,O, generating system, 30 mM glucose + 0.03 mg glucose 
oxidase; boiled guinea pig hepatic 10’ g supernatant fraction, 22.5 pg protein; total volume, 1.5 
ml, 25°C. Data are means * SD. Numbers in parentheses represent number of experiments. 
(Modified from Susick and Zannoni.”) 
ZANNONI et 01.: ALCOHOL & ENVIRONMENTAL CHEMICALS 377 




Serum B d Y  
SGOT SGPT Triglycerides Weight 
(Units/ml@) (Units/ml) (mg/100 ml) (mp/g) 
Hepatic Ascorbate 
(mg/100 g liver) 
I to 16 281 2 140(14) 64 2 24 (14) 200 2 86(12) 46 2 7 (14) 
17 to 36 111 * 26 (7) 53 2 12 (7) 213 2 101 (7) 40 2 2 (7) 
p Value' < 0.01 nsd ns < 0.05 
Baseline before Alcohol 22 2 9 (21) 17 * 8 (21) 121 37 (19) 
Values represent means 2 SD, with number of animals in parentheses, after 4.0 g ethanol/ 
kg i.p. Baseline values taken before ethanol administration were not affected by ascorbate 
concentration and were combined. 
1 unit = 4.82 X lo-' pmoles glutamate formed/min. 
' p  values calculated from a two-sided Student's 1-test. 
dnot significant, p > 0.05. 
(From Susick and Zannoni.") 
TABLE 10. Serum Enzymes and Liver Weight to Body Weight Ratios after Chronic 
Alcohol Consumption" 
Low Ascorbic Acid Dietb High Ascorbic Acid Diet' 
No Alcohol Alcohol No Alcohol Alcohol 
SGOT (units/mly 42 * 8 (5) 92 ? 34 (8)** 32 2 12 (6) 47 2 12 (12). 
SGF7 (units/ml)d I5 * 9 (5) 52 * 29 (8). 14 2 5 (6) 24 2 11 (12) 
Liver Weight 
Body Weight 
(mg/gram) 41 f 3 (6) 42 ? 10 (9) 43 2 7 (6) 38 f 10 (13) 
LI Values represent the mean 2 SD with number of animals in parentheses. 
Mean hepatic ascorbic acid concentration: no alcohol, 30 * 9 mg/ 100 g protein; alcohol, 
' Mean hepatic ascorbic acid concentration: no alcohol, 130 * 34 mg/ 100 g protein; alcohol, 20 * 6 mg/100 g protein. 
120 * 28 mg/100 g protein. 
1 unit = 4.82 x lo-' pmoles glutamate formed/min. 
* p  i 0.05 from nonalcohol control group. 
** p < 0.01 from nonalcohol control group. 
(From Susick ef a/ .M) 
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With regard to behavioral tests, ethanol consumption impaired motor coordination 
and the vitamin significantly reduced this impairment (FIG. 9). Thirteen subjects had 
a greater than 20% difference in motor coordination after ascorbic acid pretreatment. 
Eleven of these thirteen subjects had a 21-50% improvement after vitamin pretreat- 
ment; two had a decrease of 48% and 56%. Of the remaining seven subjects, one had 
an improvement in motor coordination of 14% and six had a decrease from 1% to 
20%. Pretreatment with the vitamin also protected against decrease in color discrim- 
ination after ethanol (FIG. 10). Ten subjects had a greater than 20% difference in 
color discrimination after ascorbic acid pretreatment. Nine of these had a 20- 100% 
improvement. The remaining three subjects had a 10-20% decrease in color discrim- 
ination. There was no statistically significant effect of ascorbic acid, however, on 
intellectual function. 
DISCUSSION 
The participation of ascorbic acid in the major xenobiotic metabolizing systems 
requiring endoplasmic reticulum electron transport is rather specific. The depletion 
of the vitamin does not involve an impairment leading to a general membrane alter- 
ation. Cytochrome P-450, a heme protein, and the flavin monooxygenase, a nonheme, 
FAD-requiring enzyme, are significantly decreased in deficiency.'-24 On the other hand, 
microsomal 6, reductase, a FAD-requiring enzyme, and microsomal cytochrome b,, 
a heme protein, are not affected by the depletion of the vitamin. With regard to the 
cytochrome P-450 mixed function monooxygenase and the flavin monooxygenase 
enzyme, the participation of ascorbic acid shares some similarities but also some 
differences. With either system there are no significant alterations between enzyme 
prepared from vitamin C or supplemented animals in the apparent affinity of drug 
substrates or ~ 0 f a ~ t o r s . 6 " ~ ' ~ ~ ~ ~ ~ ' ~  In addition, with purification there is a significant 
decrease in the quantity of cytochrome P-450 as well as the flavin m0nooxygenase.2~ 
With regard to cytochrome P-450, the decrease involves three specific heme isozymes 
while others are ~na l te red . '~  Also, inhibitor studies with ferrous iron chelators and 
substrate binding information indicate that the vitamin's participation, most likely, is 
at the heme-ferrous ion level, and specifically with those isozymes most affected by 
the deficiency.I6 
To date, the observed decrease in the quantity of FMO could be more general, or 
for that matter involve a disaggregation of monomeric forms of FMO resulting in a 
loss of recoverable enzyme In addition to a decrease in the quantity of 
FMO protein, vitamin C deficiency also resulted in purified FMO fractions, which 
had an obligatory need of exogenous FAD for optimal activity. Perhaps the binding 
site of FAD to apo-enzyme is jeopardized, leading to disaggregation with subsequent 
decrease in viable enzyme. In keeping with this, FMO purified from vitamin-C-deficient 
animals is highly unstable and vulnerable to marked substrate inhibition. This is not 
the case with purified cytochrome P-450 isolated from vitamin-C-deficient animals. 
FIGURE 6. Photomicrographs of the liver, hematoxylin and eosin, magnification 470X. (A) 
From animal on the low ascorbic acid diet, after 14 weeks of ethanol feeding. Note the marked, 
diffuse vacuolar change in hepatocytes, indicative of steatosis. (B) From animal on the high 
ascorbic acid diet, after 14 weeks of ethanol feeding. In contrast to A, there is no steatosis. 
(From Susick et aLM Reprinted by permission of Toxicology and Applied Pharmacology.) 1 















FIGURE 7. Effect of ascorbic acid pretreatment on blood ethanol clearance after an acute dose 
of ethanol in 20 subjects. Ascorbic acid or placebo (lactose) was given for 2 weeks prior to the 
dcohol; 1.0 gram of ascorbic acid or placebo was taken five times a day. On the test day 0.95 
gram ethanol/kg body weight was taken orally as a 30% solution in ginger ale over a 2%-h 
period. (From Susick and Zann~ni.’~ Reprinted by permission of Clinic01 PharmucologV and 
Therapeutics. ) 
Furthermore, the decrease in FMO activity in vitamin C deficiency was enhanced by 
a concomitant loss of 10-15% body weight, which was not found with cytochrome 
P-450.23 The in vivo consequences of a decreased capacity of these two major electron 
transport systems will obviously depend upon the particular xenobiotic under inves- 
tigation, that is, the potential toxicity of the substrate itself or its subsequent metab- 
olites. In addition, since both electron transport systems are affected in vitamin C 
deficiency, their contribution to metabolism and the possibility of forming toxic in- 
termediates will rely heavily on the degree to which particular species of either 
transport system becomes rate limiting. Although it is difficult to predict the ultimate 
consequences of jeopardized electron transport metabolic systems by a biochemical 
in vitro analysis, an in vivo model is at hand whereby a variety of xenobiotics could 
be tested under depletion of the vitamin and an examination of any toxicological 
consequences documented. 
In addition to the effect of ascorbic acid on the important electron transport 
systems, MFO and FMO, the vitamin partakes via its reductive property in preventing 
quinoid-type reactive intermediates from covalent binding to macromolecular pro- 
This participation was illustrated in the metabolic transformation of teins, 21.28.30.32-36.48 
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benzene or phenol, which results in electrophilic reactive quinone species, the latter 
undergoing reduction by the vitamin.” Although the precise damaging intermediate 
of benzene or phenol resulting in myelotoxicity remains to be elucidated-it may be 
a hydroxyl cyclohexadienyl radical formed from ben~ene‘~ or a semiquinone or quinone 
type metabolite of phenol-the vitamin affords in vitro pr~tection.)~ In keeping with 
these findings, when the dietary ascorbic acid was varied in the guinea pig in vivo, 
the ensuing covalent binding of benzene metabolites to hepatic or bone marrow tissue 
was inversely related to the concentration of the vitamin found in these tissues.)6 Both 
the in vitro and in vivo effect of varying amounts of ascorbic acid on covalent binding 
with benzene, however, was less than when phenol was used as a substrate. For 
example, ascorbate is capable of inhibiting the in vitro covalent binding of phenol by 
over 90% compared to 35% with benzene as a substrate. Similarly, the in vivo covalent 
binding with an i.p. administration of benzene decreased 30% in the bone marrow of 
animals on a high intake of the  ita am in.'^ This is suggestive that the most potent 











FIGURE 8. Effect of ascorbic acid pretreatment on serum triglyceride levels &r an acute dose 
of ethanol in 20 subjects. Ascorbic acid or placebo (lactose) was given for 2 weeks prior to the 
alcohol; 1.0 gram of ascorbic acid or placebo was taken five times a day. On the test day 0.95 
gram ethanol/kg body weight was taken orally as a 30% solution in ginger ale over a 2%-h 
period. (From Susick and Zann~ni.’~ Reprinted by pennission of Clinical Pharmacology and 
Therapeutics. ) 
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FIGURE 9. Effect of ascorbic acid pretreatment on motor coordination after an acute dose of 
ethanol in 20 subjects. Ascorbic acid or placebo (lactose) was given for 2 weeks prior to the 
alcohol; 1.0 gram of ascorbic acid or placebo was taken five times a day. On the test day 0.95 
gram ethanol/kg body weight was taken orally as a 30% solution in ginger ale over a 2%-h 
period. (From Susick and Zannoni.’’ Reprinted by permission of Clinical Pharmacology ond 
Therapeutics. ) 
techol, or phenol since the vitamin is extremely effective in reducing these metabolites 
and consequently preventing their interaction with macromolecular tissue sites. On 
the other hand, another possibility exists that the cellular distribution of the vitamin 
is not at a substantial concentration at the precise macromolecular site of interaction 
with metabolites of benzene. Consideration should be given, however, to the findings 
that modulation of the intake of the vitamin can alter the covalent binding of benzene 
metabolites in the bone marrow in vivo. which is the target tissue of benzene toxicity. 
In the United States at least 10 million people suffer from alcohol abuse. An 
estimated 205,000 deaths every year are attributable to that abuse, the causes ranging 
from highway fatalities to cirrhosis.” In large urban areas of the United States, cirrhosis 
has become the third most common cause of all deaths in the age group 25 to 65 
years6’ The ability of any agent to influence the effect of alcohol on the body is of 
importance. In this regard, vitamin C has been demonstrated to influence ethanol 
metabolism, toxicity, and behavioral impairment in man and  animal^^^^''^'^^'^^'.^^ 
Ascorbic acid pretreatment enhanced ethanol clearance from the blood in healthy 
human s~bjec ts . ’~ .~  We have described and characterized an ascorhic-acid-dependent 
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alcohol oxidizing system that is catalyzed by catala~e.’~ In this system, ascorbic acid 
generated a peroxide that is utilized by catalase in a peroxidatic oxidation of the 
alcohol. The ability of ascorbic acid pretreatment to enhance blood ethanol clearance 
may be due to its ability to supply peroxide and thus allow catalase to contribute to 
ethanol oxidation. 
It is well established that ethanol affects lipoprotein metabolism and that an acute 
dose increases levels of serum and hepatic t r ig ly~er ides .~~“~ Ethanol causes a number 
of events to occur that lead to increased hepatic fat levels, e.g., a stress-induced 
mobilization of fat from adipose tissues, a decrease in the rate of fatty acid oxidation, 
an increase in the rate of fatty acid synthesis, and an increase in the esterification of 
fatty acids to triglycerides. In addition, ethanol inhibits export of fat from the liver 
by impairing the synthesis and secretion of very low-density lipoproteins (VLDL), 
the export form of triglycerides. Ascorbic acid pretreatment in human subjects caused 
an increase in serum triglyceride levels.s9 The possibility that the vitamin increases 
the rate of fat transport out of the liver should be considered. This could be accom- 
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FIGURE 10. Effect of ascorbic acid pretreatment on color discrimination after an acute dose 
of ethanol in 13 subjects. Ascorbic acid or placebo (lactose) was given for 2 weeks prior to the 
alcohol; 1.0 gram of ascorbic acid or placebo was taken five times a day. On the test day 0.95 
gram ethanol/kg body weight was taken orally as a 30% solution in ginger ale over a 2%-h 
period. (From Susick and Zannoni.” Reprinted by permission of Clinical Pharmacology and 
Therapeutics. ) 
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of alcohol’s impairment of these processes. This mechanism would result in less fat 
accumulation in the liver. In keeping with this, in vivo guinea pig studies have dem- 
onstrated that ascorbic acid pretreatment results in less hepatic steatosis after chronic 
ethanol consumption.@’ Ascorbic acid may also protect the liver against direct ethanol 
toxicity, as evidenced in acute and chronic in vivo guinea pig studies where ascorbic 
acid protected against elevated SGOT and SGPT levels, indices of increased perme- 
ability and/or necrosis of hepa to~y tes .~~’~  
The participation of ascorbic acid in neurochemical events is of current interest. 
Its involvement in Na+ and K+ transport and metabolism of neurotransmitters, 
including the synthesis of catecholamines, storage of norepinephrine, and regulation 
of dopaminergic transmission, have been rep0rted.7~’~ In addition, the vitamin has 
been implicated in modulating the behavioral effects of antipsychotic drugs by influ- 
encing their binding to the dopamine recept0r.7~ With regard to ethanol’s impairment 
of behavior, ascorbic acid has been shown to prevent impaired swimming in mice 
caused by an intoxicating dose of ethan01.~’ The protective effect of ascorbic acid 
pretreatment on impaired motor coordination demonstrated in the clinical study (FIG. 
9) supports a neurochemical role for the vitamin. The protective effect is not due to 
altered blood ethanol concentrations, since ascorbic acid pretreatment had no effect 
on ethanol concentrations at the time the behavioral tests were administered. The 
mechanism of the protective action, be it through stabilization of the neuronal mem- 
brane, an effect on Na+/K+ transport, an effect on the synthesis, storage, release or 
binding of the neurotransmitters, or an as yet unknown mechanism, remains to be 
determined. 
Ascorbic acid is capable of influencing both biochemical and behavioral changes 
caused by an acute dose of ethanol in man. The influence of ascorbic acid pretreatment, 
although not observed in every subject, was greatest in those subjects with the largest 
alcohol impairment of behavior and in those subjects with the slowest rates of ethanol 
elimination after placebo pretreatment. The results of the clinical study coupled with 
the animal studies suggest that ascorbic acid may be of value in protecting against 
some harmful consequences of alcohol consumption in certain individuals. In addition, 
the determination of the exact mechanisms by which ascorbic acid acts may lead to 
the elucidation of important new biological roles for the vitamin. 
CONCLUSIONS 
Ascorbic acid is involved in the metabolism and detoxification of xenobiotics, in 
the hepatic microsomal electron transport system, in protection against binding of 
reactive intermediates, and in the metabolism of alcohol and protection against alcohol 
toxicity. Its deficiency results in a decrease of the flavin monooxygenase system (50%). 
There is a decrease in recoverable enzyme and an obligatory requirement for exogenous 
FAD. In addition, the vitamin, through its reductive properties, affords 75% protection 
against macromolecular protein binding of “reactive” intermediates of benzene or 
phenol. Furthermore, ascorbic acid participates in alcohol metabolism by generating 
a peroxide that is utilized by catalase to oxidize alcohol. The vitamin protects against 
acute and chronic alcohol toxicity. SGOT levels are lowered (50%) and fatty infil- 
tration and necrosis of hepatocytes are minimized. In clinical studies with an acute 
dose of ethanol, vitamin pretreatment enhanced ethanol clearance ( 11 -74%), increased 
serum triglycerides (33-133%), and was beneficial in behavioral responses of motor 
coordination and color discrimination in 50% of the subjects. 
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DISCUSSION OF THE PAPER 
B. LANE (Columbia University School of Public Health, New York, N.  Y): Did it 
look like there was a worsening of color vision following the pretreatment? 
V. G. ZANNONI (University of Michigan Medical School, Ann Arbor, Mich. ): Color 
vision is improved. 
M. LEVINE (National Institutes of Health, Bethesda, Md. ): Will your effects in the 
guinea pig studies on alcohol be specific for ascorbic acid in terms of increasing alcohol 
metabolism? Did you try other reducing agents or was this effect specific for alcohol 
for ascorbic acid? 
V. G. ZANNONI: We didn’t try other reducing agents in vivo but we did measure 
the glutathione levels in the two groups and they were exactly the same. However, 
in the in vitro experiments as far as alcohol metabolism is concerned, it’s relatively 
specific for ascorbic acid or analogues of ascorbic acid; other reducing agents have 
absolutely no effect. 
B. N. LADU (University of Michigan Medical School, Ann Arbor, Mich. ): Didn’t 
the involvement of the catalase system as a peroxidase require the generation of 
peroxide, which is coming from ascorbic acid, so theoretically anything that would 
generate peroxide in a similar way should bring the catalases into account. 
S. L. ROMNEY (Albert Einstein College of Medicine, Bronx, N.  Y): This is not 
meant to be facetious. On basis of your work would you recommend that liquor 
manufacturers supplement with some form of ascorbic acid? 
V. G. ZANNONI: No actually I’d recommend that people drink less and have a 
few oranges a day. 
